Overall, our study uncovered that altered m6A modifications as a novel epitranscriptomic mechanism in chemical carcinogenesis and suggested that METTL3-m6A-CDCP1 axis could be a promising therapeutic target for the treatment of chemical-induced cancers. Here, CDCP1 is linked to cancer.